June 19, 2015 / 2:30 PM / in 2 years

BUZZ-IntelliPharmaCeutics International Inc: FDA imposes new conditions

** Generic drug maker’s shares down 7 pct at $3.19

** FDA indicated that IntelliPharmaCeutics’ generic Attention Deficit Hyperactivity Disorder treatment will have to meet new conditions to prove it is as effective as existing therapy, company says

** Says FDA decision affects 4 out of 6 doses, which have only conditional approval

** Says will pursue “all reasonable courses of action” to get final approval, along with its U.S. marketing partner Par Pharmaceutical Inc

** Up to Thursday’s close, stock had risen nealry 53 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below